Study Suggests Food Can Suppress Main Dengue Fever-Like Symptoms
Clinical trial confirms Kirin Holdings’ Lactococcus lactis strain Plasma effective against the cureless and vaccineless virus
TOKYO, JAPAN - Media OutReach
- 17 September 2021 -A joint clinical
trial confirmed that continuous intake of Kirin Holdings
Company, Limited's (Kirin Holdings) Lactococcus
lactis strain Plasma (LC-Plasma)*1 for two months significantly
reduced the cumulative number of days of fever, muscle pain, joint pain, and
pain behind the eyes, which are known to be the main symptoms of dengue fever. LC-Plasma
is the same functional ingredient in Kirin Holdings' stable of IMMUSE material that
help maintain the immune system. The study was conducted by The Kirin Central
Research Institute in collaboration with Professor Dr. Sazaly Abu Bakar,
Director of the Tropical Infectious Diseases Research & Education Centre
(TIDREC) at the University of Malaya.
No Cure, No Vaccine... But Hope Against Symptoms
Arises – In Food!
There is still no definitive cure or vaccine for dengue fever. However, the study results show there is hope for dealing with symptoms. The results of a clinical trial have confirmed the suppression of dengue fever-like symptoms through a food that is safe and does not rely on medical infrastructure, reflecting a groundbreaking achievement that has the potential to provide a solution to the global social issue of dengue fever. The results of this research were presented at the 25th Annual Meeting of the Japanese Society of Travel and Health on August 22.
Since LC-Plasma activates the command
center of antiviral immunity, it has been shown to contribute to the prevention
of a wide range of viral infections other than the dengue fever virus*2. Moving forward, Kirin Holdings and the University of Malaya will
accelerate joint research aiming to verify the antiviral effects ofLC-Plasmaon tropical disease viruses other than the dengue virus.
Kirin Holdings has reported that LC-Plasma
has shown immunostimulatory effects in the body's defense against viral
infections through activation of plasmacytoid dendritic cells*3 in non-clinical
and clinical trials, and that LC-Plasma can reduce the incidence of influenza*4
in clinical trials. In collaboration with TIDREC, a WHO Collaborating Centre for Arbovirus Reference
and Research, our
collaboration will continue to verify the effects of LC-Plasma on other tropical
infectious diseases, which are expected to expand further due to global warming.
In tandem, Kirin Holdings will make LC-Plasma more accessible to more people in
Southeast Asia through alliances and business expansion, providing a solution
to a major social issue.
1.Dengue Fever Joint Research Results Summary (1 page)
ATTACHMENT
DENGUE FEVER JOINT RESEARCH RESULTS SUMMARY
Clinical trial
According to the previous research
outcomes performed by Kirin Holdings Company Limited*5, the Kirin
Central Research Institute at Kirin Holdings Company Limited and the Tropical
Infectious Diseases Research and Education Center (TIDREC) at the University of
Malaya collaborated on a joint research project on Lactococcus lactis strain Plasma (LC-Plasma) against dengue fever from
December 2019 to February 2020. During this time, approximately 100 healthy
adults of Malaysian nationality living in dengue infection cluster areas near
Kuala Lumpur, Malaysia, were asked to take a tablet containing LC-Plasma (approximately
100 billion cells) or a placebo for 8 weeks, and symptoms were measured. The
results showed that LC-Plasma significantly reduced the cumulative number of
days with dengue fever-like symptoms such as headache, joint pain, and pain behind
the eyes (Figures 1-3). These results suggest that LC-Plasma, a food product,
can help alleviate the symptoms and prevent the severity of the disease, while
the only other option currently available for dengue fever is coping therapy.
Figs. 1-3 Comparison of the cumulative number of days of
occurrence of symptoms specific to tropical diseases such as dengue fever(Representative symptoms)
Location: Laboratory for Immuno-Regulation Studies, Tropical Infectious
Disease Research and Education Centre (TIDREC), University of Malaya
Visiting Fellow: One Research Fellow appointed as visiting
professor from Kirin Holdings Company, Limited.
Research Period: From the end of 2021 to December 2023 (thereafter,
the period will be extended as the project and research progress)
Research Topics: Conduct immunological research on tropical
infectious diseases in order to , to contribute to public health in the region
and accelerate the overseas business development of Kirin Holdings' health
science business by:
- Confirmation of the efficacy of LC-Plasma against
tropical disease viruses (non-clinical research). Confirmation of the efficacy of LC-Plasma
against tropical
disease virus infection (clinical
trials).
- Confirmation of the efficacy of LC-Plasma
against tropical
disease virus infection (clinical
trials).
- Research support for LC-Plasma
business development in Southeast Asia region.
Công ty phát hành chịu trách nhiệm cho nội dung của thông báo này
About Kirin Holdings
Kirin Holdings Company, Limited is an
international company that operates in the Food & Beverages domain (Food
& Beverages businesses), Pharmaceuticals domain (Pharmaceuticals businesses),
and Health Science domain (Health Science business), both in Japan and across
the globe.
Kirin Holdings can trace its roots to Japan Brewery which was established in
1885. Japan Brewery became Kirin Brewery
in 1907. Since then, the company expanded its business with fermentation and
biotechnology as its core technologies, and entered the pharmaceutical business
in the 1980s, all of which continue to be global growth centers. In 2007, Kirin Holdings was established as
a pure holding company and is currently focusing on boosting its Health Science
domain.
Under the Kirin
Group Vision 2027
(KV 2027), a long-term management plan launched in 2019, the Kirin Group aims
to become "A global leader in CSV*, creating value across our world of Food
& Beverages to Pharmaceuticals." Going forward, the Kirin Group will
continue to leverage its strengths to create both social and economic value
through its businesses, with the aim of achieving sustainable growth in
corporate value.
* Creating Shared
Value: combined added value for consumers as well as for society at large.